Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [ see Clinical Pharmacology ( 12.3 ) ].
Source: FDA drug label - solifenacin succinate
Brand names: Solifenacin Succinate
1 interaction on record
Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [ see Clinical Pharmacology ( 12.3 ) ].
Source: FDA drug label - solifenacin succinate